Loading Results
We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.

BLU Trial

This study is currently closed to enrollment.

Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy

tube of blood

 

AGE: 18+ years old
SEX AT BIRTH: All
TYPE: Interventional Study
HEALTHY PARTICIPANTS: No
CONDITION: Systemic Mastocytosis (SM) and Indolent
LOCATION: University Hospitals Rainbow Babies & Children’s

Study Purpose

The purpose of this study is to learn more about the safety and effectiveness of an experimental drug called avapritinib (formerly called BLU285), when given to individuals who have been diagnosed with ISM.


Study ID